bioAffinity Technologies (BIAF) Free Cash Flow (2021 - 2026)

bioAffinity Technologies has disclosed Free Cash Flow across 6 years of filings, most recently posting -$3.2 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 91.01% year-over-year to -$3.2 million; the TTM figure through Mar 2026 stood at -$10.9 million (down 64.38% YoY), while the FY2025 annual figure was -$9.4 million, down 27.85% from the prior year.
• Free Cash Flow retreated to -$3.2 million in Q1 2026, from -$2.6 million in the prior quarter.
• Over the last five years, Free Cash Flow for BIAF reached as high as -$376141.0 in Q2 2022 and fell as low as -$3.2 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$1.7 million (2024), against an average of -$1.8 million.
• Annual changes were most pronounced in 2023 — Free Cash Flow plunged 262.58% — and 2025, when it climbed 29.1%.
• A 5-year view of Free Cash Flow shows it stood at -$1.3 million in 2022, then decreased by 23.24% to -$1.6 million in 2023, then declined by 4.64% to -$1.7 million in 2024, then slumped by 52.61% to -$2.6 million in 2025, then slipped by 26.31% to -$3.2 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$3.2 million, -$2.6 million, and -$2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.